Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial
Who is this study for? Patients with Liver Transplant Complications, Vasoplegia
What treatments are being studied? Angiotensin II
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age \> or = 18 years
• Liver transplantation from a deceased donor
• Model for End-stage Liver Disease Sodium (MELD-Na) score \> or = 25 at the time of transplant (not counting MELD exception points)
• Patient requiring \> 0.05 mcg/kg/min of norepinephrine (NE) during LT
Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Michael P Bokoch, M.D., Ph.D.
michael.bokoch@ucsf.edu
(415) 476-8389
Time Frame
Start Date: 2022-06-28
Estimated Completion Date: 2026-09-01
Participants
Target number of participants: 50
Treatments
Experimental: Angiotensin II (Giapreza)
Giapreza (synthetic human angiotensin II), initiated at 5 ng/kg/min and titrated to between 1.25 ng/kg/min and 40 ng/kg/min, administered by continuous intravenous infusion.
Placebo_comparator: Saline
Sterile 0.9% saline, initiated and titrated at an equivalent volume infusion rate to the study drug, administered by continuous intravenous infusion.
Authors
Related Therapeutic Areas
Sponsors
Leads: University of California, San Francisco
Collaborators: La Jolla Pharmaceutical Company